EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care .

Autor:	Hellings PW; Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals, Leuven, Belgium.; Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium., Lau S; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitaetsmedizin, Berlin, Germany., Scadding GK; Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.; Division of Immunity and Infection, University College, London, United Kingdom., Bjermer L; Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden., Backer V; Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark., Chaker AM; Department of Otorhinolaryngology and Center for Allergy and Environment (ZAUM), TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Conti DM; The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium., De Corso E; Otolaryngology Head and Neck Surgery, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy., Diamant Z; Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.; Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.; Dept of Microbiology Immunology & Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium., Djukanovic R; NIHR Southampton Biomedical Research Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Fokkens W; Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, Netherlands., Gevaert P; Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium., Gray CL; Division of Allergy, Department of Paediatrics and Child Health, University of Cape Town, Rondebosch, South Africa.; Specialist Allergist, Kidsallergy Centre, Cape Town, South Africa., Han JK; Department of Otolaryngology & Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, United States., Heaney LG; Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, United Kingdom., Hoffmann HJ; Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark., Jesenak M; Department of Pulmonology and Phthisiology, Department of Pediatrics, Department of Clinical Immunology and Allergology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia., Johansen P; Department of Dermatology, University of Zurich, Zurich, Switzerland.; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Kumaran MS; Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India., McDonald M; Mediclinic Sandton, Johannesburg, South Africa., Melén E; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet and Sachs' Children and Youth Hospital, Stockholm, Sweden., Mullol J; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain., Reitsma S; Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, Netherlands., Ryan D; Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.; International Primary Care Respiratory Group., Edinburgh, United Kingdom., Scadding G; Allergy, Royal Brompton Hospital, London, United Kingdom., Schmid-Grendelmeier P; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.; Christine-Kühne Center for Allergy research and Education CK-CARE, Davos, Switzerland., Teeling T; Patient Advisory Board of the European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium., Odemyr M; Patient Advisory Board of the European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium., Wahn U; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitaetsmedizin, Berlin, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in allergy [Front Allergy] 2023 Jul 27; Vol. 4, pp. 1236977. Date of Electronic Publication: 2023 Jul 27 (Print Publication: 2023).
DOI:	10.3389/falgy.2023.1236977
Abstrakt:	In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond. Competing Interests: HPW: Is recipient of consultancy/lecture fees or unrestricted research grants from Sanofi/Regeneron, Novartis, GSK, Medtronic and Viatris. LS: Honoraria by Allergopharma, DBV Technologies, Sanofi-Aventis, Leti, Nutricia. AD-Boards: Leo-Pharma, GSK, Sanofi-Aventis. SGK: Honoraria for articles, speaker and advisory boards: ALK, Bayer, GlaxoSmithKline, Haleon, Noucor, Sanofi- Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Board member and AR lead for EUFOREA, and Chair/ member Data Monitoring Committees on SLIT for ALK. BV: Is recipient of consultancy/lecture fees or unrestricted research grants from Sanofi/Regeneron, Novartis, GSK, AZ, ALK Abello and BORK-npc. CAM: Grants, speaker honoraria, consultancy or advisory fees and/or research support all via Technical University of Munich from Allergopharma, ALK Abello, AstraZeneca, Bencard/Allergen Therapeutics, Immunetek, GSK, Novartis, LETI, Roche, Zeller, Sanofi Genzyme, Regeneron, European Institute of Technology, Federal German Ministery of Research and Education. Travel support by EUFOREA, EAACI and DGAKI. DCE: Lecture fees and participations in experts board meeting of GSK, Novartis, Sanofi, Regeneron, Astrazeneca. DR: No conflict of interest to declare related to this work, but declares a general COI arising out of consulting pharmaceutical companies (GlaxoSmithKline, Sanofi, Kymab and Synairgen) and honoraria for speaking (GlaxoSmithKline). FW: The department of Otorhinolaryngology of the Amsterdam University Medical centre, location AMC received grants for research in Rhinology from ALK, AllergyTherapeutics, Novartis, EU, GSK, MYLAN, Sanofi-Aventis, and Zon-MW. WF: Received consultation and/or speaker fees from Dianosic, GSK, Novartis and Sanofi-Aventis/Regeneron. GP: Has participated in advisory boards and received speaker fees from ALK-Abelló, Argenx, AstraZeneca, Genentech, GSK, Novartis, Regeneron, Roche, Sanofi Genzyme, and Stallergenes- Greer. HJK: Research consultant for Sanofi, Regeneron, GlaxoSmithKline, and AstraZeneca. HLG: Has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; he has received grants from MedImmune, Novartis UK, Roche/ Genentech Inc, and Glaxo Smith Kline, Amgen, Genentech/Hoffman la Roche, Astra Zeneca, MedImmune, Glaxo Smith Kline, Aerocrine and Vitalograph; he has received sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; he has also taken part in asthma clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche, and Janssen. JM: Declares a general COI arising out of consulting pharmaceutical companies (BerlinChemie Menarini, AstraZeneca, Chiesi, Stallergenes-Greer, ALK, Novartis) and honoraria for speaking (BerlinChemie Menarini, Chiesi, Stallergenes-Greer, Sanofi, Takeda, Novartis). ME: Has received lecture and/or advisory board fees from Airsonett, ALK, AstraZeneca, Chiesi, Novartis and Sanofi outside the submitted work. MJ: Grants from Mylan Pharma, Noucor/Uriach Group, and GSK. Personal and advisory board fees from Sanofi-Genzyme & Regeneron, Novartis, Mylan Pharma, Noucor/Uriach Group, Mitsubishi-Tanabe, Menarini, UCB, AstraZeneca, GSK, and MSD. RS: Declares a general COI arising out of consulting pharmaceutical companies and/or advisory boards (GlaxoSmithKline, Sanofi, Novartis). SG: Have received speaker fees from ALK-Abello, Meda, Glenmark and funding to attend a conference from GSK and Mylan/Meda. WU: Has received honoraria for advising and lecturing from Viatris, Stallergenes, and ALK. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2023 Hellings, Lau, Scadding, Bjermer, Backer, Chaker, Conti, De Corso, Diamant, Djukanovic, Fokkens, Gevaert, Gray, Han, Heaney, Hoffmann, Jesenak, Johansen, Kumaran, McDonald, Melén, Mullol, Reitsma, Ryan, Scadding, Schmid-Grendelmeier, Teeling, Odemyr and Wahn.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu